Viral Vector Commercialization – Part 2: Best Practices In Process Validation Lifecycle

Advancement in the ability for viral vectors to efficiently deliver genetic material to target cells is demonstrating the potential of gene therapies and vaccines to revolutionize medicine and driving demand for viral vector-mediated therapies. Employing a robust validation lifecycle with various assessments and studies is crucial for ensuring the safety, efficacy, and quality of viral vectors.

Learn more about how the validation lifecycle establishes a strong foundation for the successful translation of viral vector-based therapies from the laboratory to the clinic.